Drug class
Atypical antipsychotic; piperidinyl-benzisoxazole derivative
Mechanism of action
The mechanism of action in schizophrenia and acute manic or mixed episodes of bipolar I disorder is unknown. Clinical efficacy may be mediated through a combination of dopamine D2 and serotonin 5-HT2 receptor antagonism. Milsaperidone and iloperidone rapidly interconvert in vivo; the receptor-binding profile is similar to iloperidone.
General use cases
- Treatment of schizophrenia in adults under the US BYSANTI indication (initial US approval 2026)
- Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults under the US BYSANTI indication; do not infer a distinct mechanism from its pharmacodynamic binding profile
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
